Back
United States Cellular Vs. Sarepta Therapeutics Industry Stock Comparison
Buy
71
USM
United States Cellular
Last Price:
65.01
Seasonality Move:
2.81%
Sell
49
SRPT
Sarepta Therapeutics
Last Price:
130.47
Seasonality Move:
14.88%
Buy
71
United States Cellular (USM)
is a Buy
Is United States Cellular a Buy, Sell or Hold?
- The current United States Cellular [USM] share price is $65.00. The Score for USM is 71, which is 42% above its historic median score of 50, and infers lower risk than normal.
- USM is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
49
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $130.50. The Score for SRPT is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
- SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
USM Stock Price Chart
What is United States Cellular's stock price today?
-
The United States Cellular share price today is $65.00
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and USM is experiencing slight buying pressure.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $130.50
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.
USM Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 1.29 | Buy |
| Relative Strength Index (14 RSI): | 60.41 | Buy |
| Chaikin Money Flow: | 49180 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (60.31 - 64.39) | Buy |
| Bollinger Bands (100): | (53.12 - 60.82) | Buy |
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -2.3 | Sell |
| Relative Strength Index (14 RSI): | 64.59 | Buy |
| Chaikin Money Flow: | 3149400 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (111.02 - 128.88) | Buy |
| Bollinger Bands (100): | (119.18 - 142.3) | Sell |
USM Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 63.3 | Buy |
| 20-day SMA: | 62.61 | Buy |
| 50-day SMA: | 59.51 | Buy |
| 200-day SMA: | 49.38 | Buy |
| 8-day EMA: | 63.75 | Buy |
| 20-day EMA: | 62.61 | Buy |
| 50-day EMA: | 60.16 | Buy |
| 200-day EMA: | 51.71 | Buy |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 112.07 | Buy |
| 20-day SMA: | 117.27 | Buy |
| 50-day SMA: | 121.92 | Buy |
| 200-day SMA: | 129.99 | Buy |
| 8-day EMA: | 116.28 | Buy |
| 20-day EMA: | 117.14 | Buy |
| 50-day EMA: | 121.91 | Buy |
| 200-day EMA: | 125.98 | Buy |
United States Cellular Earnings Growth & USM Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.70 per share, and a decrease next year of $0.05 per share.
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.87 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $8.76 per share.
United States Cellular Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Sarepta Therapeutics Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||